Early circulating tumor DNA dynamics as a pan‐tumor biomarker for long‐term clinical outcome in patients treated with durvalumab and tremelimumab

There is an urgent need to identify biomarkers of early response that can accurately predict the benefit of immune checkpoint inhibitors (ICI). Patients receiving durvalumab/tremelimumab had tumor samples sequenced before treatment (baseline) to identify variants for the design of a personalized cir...

Descripción completa

Detalles Bibliográficos
Autores principales: Kansara, Maya, Bhardwaj, Neeru, Thavaneswaran, Subotheni, Xu, Chang, Lee, Jessica K., Chang, Lo‐Bin, Madison, Russell W., Lin, Frank, Hsu, Eugene, Patel, Vipul Kumar, Aleshin, Alexey, Oxnard, Geoffrey R., Simes, John, Nimeiri, Halla, Thomas, David M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9892824/
https://www.ncbi.nlm.nih.gov/pubmed/36426653
http://dx.doi.org/10.1002/1878-0261.13349

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9892824/
https://www.ncbi.nlm.nih.gov/pubmed/36426653
http://dx.doi.org/10.1002/1878-0261.13349

Ejemplares similares